BLINCYTO® (blinatumomab) is a prescription medication used to treat a certain type of acute lymphoblastic leukemia (ALL) in adults and children. ...read more
*In a study of 405 adults with ALL, 271 were treated with BLINCYTO® and 134 with chemotherapy. People on BLINCYTO®
lived nearly twice as long† compared to people on chemotherapy.1
†7.7 months (median overall survival) with BLINCYTO® vs 4.0 months with chemotherapy. Median overall survival is defined as the length of time from the start of treatment to when half of the patients in a treatment group are still alive.1,2
What is the most important information I should know about BLINCYTO®?
Who should not receive BLINCYTO®?
What should I avoid while receiving BLINCYTO®?
Before receiving BLINCYTO®, tell your health care provider about all of your medical conditions, including if you or your child:
BLINCYTO® (blinatumomab) is a prescription medication used to treat a certain type of acute lymphoblastic leukemia (ALL) in adults and children. ALL is a cancer of the blood and bone marrow in which a particular kind of white blood cell is replicating out of control.
What is the most important information I should know about BLINCYTO®?
References: 1. BLINCYTO® (blinatumomab) prescribing information, Amgen. 2. National Cancer Institute. NCI Dictionary of Cancer Terms. https://www.cancer.gov/publications/dictionaries/cancer-terms. Accessed October 9, 2019.